Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined traditional Chinese and western medicine for stroke via gut flora regulation
ChiCTR1800015236Phase 4Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Apr 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, double-blind trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis and Xinglou Chengqi Decoction in ischemic stroke (3 arms), sponsored by Beijing Friendship Hospital. Primary endpoints: Interleukin-6 levels in peripheral blood, Interleukin-10 levels in peripheral blood and 6 more. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalisXinglou Chengqi Decoction
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1800015236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015236.